Vivodyne

Vivodyne is a biotechnology company founded in 2020, focusing on preclinical drug development using lab-grown human organ tissues, robotics, AI, and machine learning. The company aims to improve the accuracy and efficiency of drug testing while reducing reliance on animal models. Its flagship platform, Pipeline V, utilizes lab-grown tissues to provide more relevant and ethical preclinical testing solutions.

Headquartered in Philadelphia, Vivodyne has developed advanced technologies that create 3D, vascularized human tissues from patient-derived cells. This innovative approach allows for high-throughput studies and the generation of predictive human data. The company has received significant funding, including a $38 million investment led by Khosla Ventures, and has been recognized as one of Fast Company's "World's Most Innovative Small but Mighty Companies" in 2022.

Vivodyne collaborates with biopharma organizations to enhance drug discovery and development processes, offering services such as drug testing on lab-grown tissues and automated generation of physiological insights. The leadership team includes experts in bioengineering, robotics, and biotech, ensuring a strong foundation for the company's mission.